로딩 중…
지수 로딩 중…
DAEWOONG CO.,LTD
003090· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩17,110+5.62%
2026-08-04
Financials
Valuation Metrics
DAEWOONG CO.,LTD's Market Cap is ₩9948B. At end of 2025 it was ₩1.3T. Ranked #292 of 2,436 in KR market (top 12%), #218 of 787 on KOSPI (top 28%), #34 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 994.81B KRW | KR#292/2,436 Sec#34/234 |
| Revenue | 2.08T KRW | KR#240/2,436 Sec#5/234 |
| Net Income | 246.65B KRW | KR#118/2,436 Sec#4/234 |
| Total Assets | 3.41T KRW | KR#215/2,436 Sec#5/234 |
| Net Assets | 1.85T KRW | KR#192/2,436 Sec#6/234 |
| Employees | 349 | KR#687/2,436 Sec#62/234 |
| Value | ||
| P/E | 4.03x | KR#200/2,436 Sec#7/234 |
| P/B | 0.54x | KR#868/2,436 Sec#40/234 |
| PEG | 0.07x | KR#334/2,436 Sec#18/234 |
| P/S | 0.48x | KR#891/2,436 Sec#36/234 |
| EV/EBITDA | 7.67x | KR#437/2,436 Sec#15/234 |
| FCF Yield | -3.74% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 13.31% | KR#316/2,436 Sec#19/234 |
| ROA | 7.24% | KR#401/2,436 Sec#31/234 |
| Op. Margin | 11.95% | KR#393/2,436 Sec#34/234 |
| Revenue Growth | 2.34% | KR#1,297/2,436 Sec#119/234 |
| Earnings Growth | 54.31% | KR#548/2,436 Sec#30/234 |
| Financial Health | ||
| Debt Ratio | 183.90% | KR#1,570/2,436 Sec#178/234 |
| Total Debt | 1.17T KRW | KR#179/2,436 Sec#3/234 |
| FCF | -37.22B KRW | KR#2,034/2,436 Sec#200/234 |
| Cash | 259.69B KRW | KR#231/2,436 Sec#5/234 |
| Current Ratio | 1.20x | KR#1,573/2,436 Sec#164/234 |
| Net Debt/EBITDA | 3.66x | KR#1,008/2,436 Sec#76/234 |
| Dividend | ||
| Div. Yield | 1.24% | KR#1,090/2,436 Sec#62/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -22.58% | KR#1,452/2,436 Sec#117/234 |
| 1M Return | -3.71% | KR#1,064/2,436 Sec#92/234 |
| From 52W High | -44.09% | KR#959/2,436 Sec#73/234 |
| 1Y MDD | -46.00% | KR#748/2,436 Sec#62/234 |
| Trading | ||
| Volume | 62,183 shares | KR#1,300/2,436 Sec#123/234 |
| Foreign Own. | 5.10% | KR#786/2,436 Sec#75/234 |
| Per Share | ||
| EPS | 3,167 KRW | KR#269/2,436 Sec#16/234 |
| BPS | 29,627 KRW | KR#353/2,436 Sec#24/234 |
Company Info
Daewoong, established in 1961 as Daehan Vitamin Industry Co., Ltd. and listed in 1973, transitioned to a holding company through a spin-off in 2002. As the holding company of a global healthcare group, it owns 36 subsidiaries including Daewoong Pharmaceutical, engaging in pharmaceutical manufacturing and investment. Daewoong focuses on enhancing global market penetration with Fexuclue, Enavlo, and Nabota, while strengthening K-Bio's status. The company is headquartered in Seongnam, Gyeonggi Province.